Ecteinascidin 743 interferes with the activity of EWS-FLI1 in ewing sarcoma cells

Neoplasia

Volumn 13, Issue 2, 2011, Pages 145-153

  Grohar, Patrick J ^a   Griffin, Laurie B ^a   Yeung, Choh ^a   Chen, Qing Rong ^a   Pommier, Yves ^a   Khanna, Chand ^a   Khan, Javed ^a   Helman, Lee J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; LUCIFERASE; RNA BINDING PROTEIN EWS; TRABECTEDIN; TRANSCRIPTION FACTOR FLI 1;

ARTICLE; CELL STRAIN; CELL STRAIN HT1080; CELL TYPE; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; EWING SARCOMA; GENE; GENE CONSTRUCT; HUMAN; HUMAN CELL; NR0B1 GENE; OSTEOSARCOMA; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; RHABDOMYOSARCOMA; SARCOMA CELL; SYNOVIAL SARCOMA;

EID: 79951471957     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101202     Document Type: Article

References (43)

1. Gurney JG, Swensen AR, and Bulterys M (1999). In Cancer Incidence and Survivalamong Children and Adolescents: United States SEER Program 1975-1995. LA Gloeker Ries, MA Smith, and JG Gurney (Eds). National Cancer Institute, Bethesda. pp. 99-110.
2. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, et al. (1992). Gene fusion with an ETS DNAbindingdomain caused by chromosome translocation in human tumours. Nature 359, 162-165.
3. Mao X, Miesfeldt S, Yang H, Leiden JM, and Thompson CB (1994). The FLI-1and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities. J Biol Chem 269, 18216-18222.
4. Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M, Thomas G, and Ghysdael J (1994). DNA-binding and transcriptional activation propertiesof the EWS-FLI-1 fusion protein resulting from the t(11;22) translocationin Ewing sarcoma. Mol Cell Biol 14, 3230-3241.
5. Hancock JD and Lessnick SL (2008). A transcriptional profiling meta-analysisreveals a core EWS-FLI gene expression signature. Cell Cycle 7, 250-256.
6. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, and Kovar H (2009). Amolecular function map of Ewing's sarcoma. PLoS One 4, e5415.
7. Owen LA, Kowalewski AA, and Lessnick SL (2008). EWS/FLI mediates transcriptionalrepression via NKX2.2 during oncogenic transformation in Ewing'ssarcoma. PLoS One 3, e1965.
8. Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE, and Delattre O (2001). Analysis of the expression of cell cycle regulators in Ewingcell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 20, 3258-3265.
9. Garcia-Aragoncillo E, Carrillo J, Lalli E, Agra N, Gomez-Lopez G, Pestana A, and Alonso J (2008). DAX1, a direct target of EWS/FLI1 oncoprotein, is aprincipal regulator of cell-cycle progression in Ewing's tumor cells. Oncogene 27, 6034-6043.
10. Ramakrishnan R, Fujimura Y, Zou JP, Liu F, Lee L, Rao VN, and Reddy ES (2004). Role of protein-protein interactions in the antiapoptotic function of EWS-Fli-1. Oncogene 23, 7087-7094.
11. Gascoyne DM, Thomas GR, and Latchman DS (2004). The effects of Brn-3aon neuronal differentiation and apoptosis are differentially modulated by EWSand its oncogenic derivative EWS/Fli-1. Oncogene 23, 3830-3840.
12. Matsunobu T, Tanaka K, Nakamura T, Nakatani F, Sakimura R, Hanada M, Li X, Okada T, Oda Y, Tsuneyoshi M, et al. (2006). The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors. Cancer Res 66, 803-811.
13. Maksimenko A and Malvy C (2005). Oncogene-targeted antisense oligonucleotidesfor the treatment of Ewing sarcoma. Expert Opin Ther Targets 9, 825-830.
14. Aune GJ, Furuta T, and Pommier Y (2002). Ecteinascidin 743: a novel anticancerdrug with a unique mechanism of action. Anticancer Drugs 13, 545-555.
15. Fayette J, Coquard IR, Alberti L, Boyle H, Meeus P, Decouvelaere AV, Thiesse P, Sunyach MP, Ranchere D, and Blay JY (2006). ET-743: a novel agent with activityin soft-tissue sarcomas. Curr Opin Oncol 18, 347-353.
16. Schoffski P, Dumez H, Wolter P, Stefan C, Wozniak A, Jimeno J, and VanOosterom AT (2008). Clinical impact of trabectedin (ecteinascidin-743) inadvanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 9, 1609-1618.
17. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, et al. (2005). Phase II study of ET-743in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23, 576-584.
18. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, et al. (2004). Phase II study of ecteinascidin-743in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22, 890-899.
19. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, et al. (2004). Phase II and pharmacokineticstudy of ecteinascidin 743 in patients with progressive sarcomas of softtissues refractory to chemotherapy. J Clin Oncol 22, 1480-1490.
20. Dileo P, Grosso F, Casanova M, Jimeno J, Marsoni S, Sanfilippo R, Podda M, Ferrari S, Bertulli R, and Casali PG (2007). American Society of Clinical Oncology(ASCO). Chicago, IL.
21. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, et al. (2001). Ecteinascidin-743: a marinederivedcompound in advanced, pretreated sarcoma patients-preliminary evidenceof activity. J Clin Oncol 19, 1248-1255.
22. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, et al. (2007). Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8, 595-602.
23. Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, et al. (2009). Trabectedin (ET-743) promotesdifferentiation in myxoid liposarcoma tumors. Mol Cancer Ther 8, 449-457.
24. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, and Kohn KW (1996). DNA sequence- and structure-selective alkylation of guanine N2in the DNA minor groove by ecteinascidin 743, a potent antitumor compoundfrom the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35, 13303-13309.
25. Seaman FC and Hurley L (1998). Molecular basis for the DNA sequence selectivityof ecteinascidin 736 and 743: evidence for the dominant role of directreadout via hydrogen bonding. J Am Chem Soc 120, 13028-13041.
26. Zewail-Foote M and Hurley LH (1999). Ecteinascidin 743: a minor groove alkylatorthat bends DNA toward the major groove. J Med Chem 42, 2493-2497.
27. Friedman D, Hu Z, Kolb EA, Gorfajn B, and Scotto KW (2002). Ecteinascidin-743inhibits activated but not constitutive transcription. Cancer Res 62, 3377-3381.
28. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, and Mantovani R (2000). Interference of transcriptional activation by the antineoplastic drugecteinascidin-743. Proc Natl Acad Sci USA 97, 6780-6784.
29. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, et al. (2001). Antiproliferativeactivity of ecteinascidin 743 is dependent upon transcription-coupled nucleotideexcisionrepair. Nat Med 7, 961-966.
30. Zewail-Foote M, Li VS, Kohn H, Bearss D, Guzman M, and Hurley LH (2001). The inefficiency of incisions of ecteinascidin 743-DNA adducts bythe Uvr ABC nuclease and the unique structural feature of the DNA adductscan be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 8, 1033-1049.
31. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, and D'Incalci M (2001). Unique pattern of ET-743 activity in different cellular systemswith defined deficiencies in DNA-repair pathways. Int J Cancer 92, 583-588.
32. Aune GJ, Takagi K, Sordet O, Guirouilh-Barbat J, Antony S, Bohr VA, and Pommier Y (2008). Von Hippel-Lindau-coupled and transcription-couplednucleotide excision repair-dependent degradation of RNA polymerase II in responseto trabectedin. Clin Cancer Res 14, 6449-6455.
33. Guirouilh-Barbat J, Redon C, and Pommier Y (2008). Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell 19, 3969-3981.
34. Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA, and Larsen AK (2007). Replication and homologous recombinationrepair regulate DNA double-strand break formation by the antitumor alkylatorecteinascidin 743. Proc Natl Acad Sci USA 104, 13062-13067.
35. Van Valen F (1999). Human Cell Culture. Kluwer, London, UK.
36. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichmentanalysis: a knowledge-based approach for interpreting genome-wide expressionprofiles. Proc Natl Acad Sci USA 102, 15545-15550.
37. Graves BJ and Petersen JM (1998). Specificity within the ets family of transcriptionfactors. Adv Cancer Res 75, 1-55.
38. Carlsson P and Mahlapuu M (2002). Forkhead transcription factors: key playersin development and metabolism. Dev Biol 250, 1-23.
39. da Costa RM, Riou L, Paquola A, Menck CF, and Sarasin A (2005). Transcriptionalprofiles of unirradiated or UV-irradiated human cells expressing either the cancerprone XPB/CS allele or the noncancer-prone XPB/TTD allele. Oncogene 24, 1359-1374.
40. Newman JC, Bailey AD, and Weiner AM (2006). Cockayne syndrome group Bprotein (CSB) plays a general role in chromatin maintenance and remodeling. Proc Natl Acad Sci USA 103, 9613-9618.
41. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, and Lemischka IR (2002). A stem cell molecular signature. Science 298, 601-604.
42. Martinez N, Sanchez-Beato M, Carnero A, Moneo V, Tercero JC, Fernandez I, Navarrete M, Jimeno J, and Piris MA (2005). Transcriptional signature of ecteinascidin 743 (Yondelis, trabectedin) in human sarcoma cells explanted fromchemo-naive patients. Mol Cancer Ther 4, 814-823.
43. Yuan L, Nikolova-Krstevski V, Zhan Y, Kondo M, Bhasin M, Varghese L, Yano K, Carman CV, Aird WC, and Oettgen P (2009). Anti-inflammatory effects of the ETS factor ERG in endothelial cells are mediated through transcriptionalrepression of the interleukin-8 gene. Circ Res 104, 1049-1057.